MedTrace Logo

Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

NCT03460522 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2022-11-02

No results posted yet for this study

Summary

The trial proposed to evaluate the efficacy and safety of an inotuzumab ozogamicin followed by maintenance treatment in patients with acute lymphoblastic leukemia older than 56 years

Conditions

  • Precursor Cell Lymphoblastic Leukemia

Interventions

DRUG

Inotuzumab ozogamicin

Patients will receive standard of care chemotherapy (only maintenance) after Inotuzumab Ozogamicin.

Sponsors & Collaborators

  • Nicola Goekbuget

    lead OTHER

Principal Investigators

  • Matthias Stelljes, MD · Universität Münster

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
56 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-02
Primary Completion
2025-06-30
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03460522 on ClinicalTrials.gov